CLAIMS

1. A preparation for prevention or treatment of type I diabetes, comprising (A) at least one member selected from the group consisting of proinsulin, insulin, insulin A chain, insulin B chain, fragments thereof and variants thereof, and (B) α-galactosylceramide; and

wherein the component (A) and the component (B) are contained in a liposome.

2. The preparation according to claim 1, wherein the component (A) is at least one member selected from the group consisting of proinsulin, insulin B chain, fragments thereof and variants thereof.

3. The preparation according to claim 1 or 2, wherein the component (B) is KRN7000.

4. The preparation according to any one of claims 1 to 3, wherein the component (B) is contained in a liposome.

~~5. The preparation according to any one of claims 1 to 4, wherein the component (A) and the component (B) are contained in a liposome.~~

~~6~~5. The preparation according to any one of claims 1 to ~~5~~4, wherein the preparation is ~~used~~ for use in the prevention of type I diabetes.

~~7~~6. The preparation according to any one of claims 1 to ~~6~~5, wherein the preparation is to be administered in the form of subcutaneous or intraperitoneal administration.

~~8~~7. Use of a preparation comprising (A) at least one member selected from the group consisting of proinsulin, insulin, insulin A chain, insulin B chain, fragments thereof and variants thereof, and (B) α-galactosylceramide, for the manufacture of an agent for the prevention or treatment of type I diabetes; and wherein the component (B)

is contained in a liposome.

~~9~~8. Use according to claim ~~8~~7, wherein the component (A) is at least one member selected from the group consisting of proinsulin, insulin B chain, fragments thereof and variants thereof.

~~10~~9. Use according to claim ~~8~~7 or ~~9~~8, wherein the component (B) is KRN7000.

~~11. Use according to any one of claims 8 to 10, wherein the component (B) is contained in a liposome.~~

~~12~~10. Use according to any one of claims ~~8~~7 to ~~11~~9, wherein the component (A) and the component (B) are contained in a liposome.

~~13~~11. Use according to any one of claims ~~8~~7 to ~~13~~10, wherein the preparation is administered in the form of subcutaneous or intraperitoneal administration.